Eledon Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ELDN Nasdaq 2836 eledon.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Feb 5th, 2026 2:10 pm
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium - Jan 23rd, 2026 5:00 am
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook - Jan 8th, 2026 2:05 pm
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference - Dec 1st, 2025 5:00 am
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - Nov 18th, 2025 2:05 pm
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results - Nov 14th, 2025 3:00 pm
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Nov 12th, 2025 5:56 am
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Nov 11th, 2025 3:26 pm
Assessing Eledon Pharmaceuticals (ELDN) Valuation After Phase 2 Kidney Transplant Trial Results and Phase 3 Prospects - Nov 9th, 2025 8:15 pm
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting - Nov 6th, 2025 4:30 pm
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference - Nov 5th, 2025 5:00 am
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting - Oct 17th, 2025 5:00 am
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is largely controlled by institutional shareholders who own 51% of the company - Oct 9th, 2025 6:08 am
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association - Sep 24th, 2025 2:05 pm
2 ‘Strong Buy’ Stocks That Wall Street Believes Can Soar 360% to 780% - Sep 23rd, 2025 5:30 am
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025 - Aug 29th, 2025 5:00 am
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results - Aug 14th, 2025 2:20 pm
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation - Aug 6th, 2025 2:01 pm
Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress - Jul 31st, 2025 9:40 pm
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025 - Jul 30th, 2025 2:05 pm